AGC Biologics, Faron to manufacture cancer immunotherapy

By The Science Advisory Board staff writers

Contract development and manufacturing organization AGC Biologics has formed a cancer immunotherapy partnership with Faron Pharmaceuticals.

Under the deal, AGC will manufacture the biopharmaceutical firm's Clevegen cancer immunotherapy treatment. A humanized anti-Clever-1 antibody, Clevegen targets Clever-1-positive tumor-associated macrophages and converts these highly immunosuppressive M2 macrophages into immune-stimulating M1 macrophages. The macrophage-directed immuno-oncology switch may be used alone or in combination with other cancer treatments, according to the companies.

AGC and Faron noted that data from Faron's ongoing phase II MATINS trial have shown that Clevegen is safe and well-tolerated. In addition, there have been early clinical benefits in patients who have exhausted all other treatment options, the firms said.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking